References
- Iacobone M, Masi G, Barzon L, et al. Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg. 2009;394:817–825.
- Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery. 1990;108:1006–1012.
- Szabó J, Heath B, Hill VM, et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet. 1995;56:944–950.
- Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32:676–680.
- Kutcher MR, Rigby MH, Bullock M, et al. Hyperparathyroidism-jaw tumor syndrome. Head Neck. 2013;35:E175–E177.
- Bradley KJ, Hobbs MR, Buley ID, et al. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med. 2005;257:18–26.
- Fujikawa M, Okamura K, Sato K, et al. Familial isolated hyperparathyroidism due to multiple adenomas associated with ossifying jaw fibroma and multiple uterine adenomyomatous polyps. Eur J Endocrinol. 1998;138:557–561.
- Wolff EF, Hill MJ, Simonds WF, et al. Aromatase inhibitor treatment of menorrhagia and subsequent pregnancy in a patient with familial hyperparathyroidism–jaw tumor syndrome. Fertil Steril. 2012;98:1616–1619.
- Dal Cin P, Vanni R, Marras S, et al. Four cytogenetic subgroups can be identified in endometrial polyps. Cancer Res. 1995;55:1565–1568.
- Pal L, Niklaus AL, Kim M, et al. Heterogeneity in endometrial expression of aromatase in polyp-bearing uteri. Hum Reprod. 2008;23:80–84.
- Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421–432.
- Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21:591–598.